Analyst Reiterates Buy on COMP360 Amid Accelerated Regulatory Momentum, Maintains $70 Price Target

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on COMPASS Pathways, with a price target of $70.00.

Patrick Trucchio has given his Buy rating due to a combination of factors related to COMP360’s regulatory momentum and potential launch timing. He highlights that the FDA has already granted COMPASS a rolling new drug application submission and review based on robust Phase 3 data, signaling strong confidence in the therapy’s efficacy and safety. In his view, this framework, combined with two successful Phase 3 primary endpoint readouts and over 1,000 patients treated, significantly de-risks the development path.

Trucchio also points to the newly awarded Commissioner’s National Priority Voucher and the recent Executive Order as key accelerators for both FDA review and Drug Enforcement Administration rescheduling. He believes these measures can shorten the review period and allow rescheduling work to proceed alongside, rather than after, FDA assessment, potentially bringing forward commercialization into the 2026–2027 window. Reflecting this improved visibility and speed to market, he reiterates a Buy rating and maintains his $70 price target, unchanged from prior estimates.

In another report released yesterday, LifeSci Capital also reiterated a Buy rating on the stock with a $23.00 price target.